BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lea AP, Faulds D. Ritonavir: . Drugs 1996;52:541-6. [DOI: 10.2165/00003495-199652040-00007] [Cited by in Crossref: 63] [Cited by in F6Publishing: 50] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Misson J, Clark W, Kendall MJ. Therapeutic advances: protease inhibitors for the treatment of HIV-1 infection. Journal of Clinical Pharmacy and Therapeutics 1997;22:109-17. [DOI: 10.1111/j.1365-2710.1997.tb00004.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
2 Back DJ, Khoo SH, Gibbons SE, Merry C. The role of therapeutic drug monitoring in treatment of HIV infection. Br J Clin Pharmacol 2001;51:301-8. [PMID: 11318764 DOI: 10.1046/j.1365-2125.2001.01380.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 2.0] [Reference Citation Analysis]
3 Jayasekara D, Aweeka FT, Rodriguez R, Kalayjian RC, Humphreys MH, Gambertoglio JG. Antiviral Therapy For HIV Patients With Renal Insufficiency: . Journal of Acquired Immune Deficiency Syndromes 1999;21:384. [DOI: 10.1097/00042560-199908150-00005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
4 Kast RE. The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs-disulfiram and ritonavir. Chin J Cancer 2015;34:161-5. [PMID: 25963312 DOI: 10.1186/s40880-015-0010-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
5 Jayasekara D, Aweeka FT, Rodriguez R, Kalayjian RC, Humphreys MH, Gambertoglio JG. Antiviral Therapy For HIV Patients With Renal Insufficiency: . JAIDS Journal of Acquired Immune Deficiency Syndromes 1999;21:384. [DOI: 10.1097/00126334-199908150-00005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
6 Faour WH, Choaib A, Issa E, Choueiry FE, Shbaklo K, Alhajj M, Sawaya RT, Harhous Z, Alefishat E, Nader M. Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. Inflamm Res 2021. [PMID: 34802072 DOI: 10.1007/s00011-021-01520-8] [Reference Citation Analysis]
7 Dhore PW, Dave VS, Saoji SD, Bobde YS, Mack C, Raut NA. Enhancement of the aqueous solubility and permeability of a poorly water soluble drug ritonavir via lyophilized milk-based solid dispersions. Pharm Dev Technol 2017;22:90-102. [PMID: 27291246 DOI: 10.1080/10837450.2016.1193193] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
8 Ghosh AK, Anderson DD, Mitsuya H. The FDA Approved HIV ‐1 Protease Inhibitors for Treatment of HIV / AIDS. Burger's Medicinal Chemistry and Drug Discovery. Wiley; 2003. pp. 1-74. [DOI: 10.1002/0471266949.bmc224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Vardanyan R, Hruby V. Antiviral Drugs. Synthesis of Best-Seller Drugs. Elsevier; 2016. pp. 687-736. [DOI: 10.1016/b978-0-12-411492-0.00034-1] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
10 Ganta KK, Chaubey B. Endoplasmic reticulum stress leads to mitochondria-mediated apoptosis in cells treated with anti-HIV protease inhibitor ritonavir. Cell Biol Toxicol 2019;35:189-204. [DOI: 10.1007/s10565-018-09451-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
11 Li X, Chan WK. Transport, metabolism and elimination mechanisms of anti-HIV agents. Advanced Drug Delivery Reviews 1999;39:81-103. [DOI: 10.1016/s0169-409x(99)00021-6] [Cited by in Crossref: 56] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
12 Temple ME, Koranyi KI, Nahata MC. The Safety and Antiviral Effect of Protease Inhibitors in Children. Pharmacotherapy 2001;21:287-94. [DOI: 10.1592/phco.21.3.287.34202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
13 Xie X, Muruato AE, Zhang X, Lokugamage KG, Fontes-Garfias CR, Zou J, Liu J, Ren P, Balakrishnan M, Cihlar T, Tseng CK, Makino S, Menachery VD, Bilello JP, Shi PY. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. bioRxiv 2020:2020. [PMID: 32607511 DOI: 10.1101/2020.06.22.165712] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
14 Enting RH, Hoetelmans RM, Lange JM, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system: . AIDS 1998;12:1941-55. [DOI: 10.1097/00002030-199815000-00005] [Cited by in Crossref: 134] [Cited by in F6Publishing: 126] [Article Influence: 5.6] [Reference Citation Analysis]
15 Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, Osmond DH. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004;18:81-8. [PMID: 15090833 DOI: 10.1097/00002030-200401020-00010] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Charbe NB, Zacconi FC, Amnerkar N, Ramesh B, Tambuwala MM, Clementi E. Bio-analytical Assay Methods used in Therapeutic Drug Monitoring of Antiretroviral Drugs-A Review. CDTH 2019;14:16-57. [DOI: 10.2174/1574885514666181217125550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Gonzalez A, Stuart-Smith N, McAskill R, Pozniak A, Everall I. Psychotropic medications and HIV medicine: A rational approach. Int J Psychiatry Clin Pract 1999;3:229-36. [PMID: 24921225 DOI: 10.3109/13651509909068389] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
18 Khoo SH, Gibbons SE, Back DJ. Therapeutic drug monitoring as a tool in treating HIV infection. AIDS 2001;15 Suppl 5:S171-81. [PMID: 11816166 DOI: 10.1097/00002030-200100005-00021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
19 Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, Osmond DH. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004;18:81-8. [PMID: 15090833 DOI: 10.1097/00002030-200401020-00010] [Cited by in Crossref: 202] [Cited by in F6Publishing: 192] [Article Influence: 11.2] [Reference Citation Analysis]
20 Dasgupta A, Okhuysen PC. Pharmacokinetic and Other Drug Interactions in Patients With AIDS: . Therapeutic Drug Monitoring 2001;23:591-605. [DOI: 10.1097/00007691-200112000-00001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
21 Rolla VC, da Silva Vieira MA, Pereira Pinto D, Louren??o MC, de Jesus CDS, Gon??alves Morgado M, Ferreira Filho M, Werneck-barroso E. Safety, Efficacy and Pharmacokinetics of Ritonavir 400mg/Saquinavir 400mg Twice Daily plus Rifampicin Combined Therapy in HIV Patients with Tuberculosis: . Clinical Drug Investigation 2006;26:469-79. [DOI: 10.2165/00044011-200626080-00005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
22 Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, Kobayashi T, Maeda Y, Shetty B, Webber S. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001;45:1086-93. [PMID: 11257019 DOI: 10.1128/AAC.45.4.1086-1093.2001] [Cited by in Crossref: 99] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
23 Mccance-katz EF, Rainey PM, Friedland G, Jatlow P. The Protease Inhibitor Lopinavir-Ritonavir May Produce Opiate Withdrawal in Methadone-Maintained Patients. Clinical Infectious Diseases 2003;37:476-82. [DOI: 10.1086/376907] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 4.9] [Reference Citation Analysis]
24 Back DJ, Khoo SH, Gibbons SE, Reynolds H, Tjia JF, Merry C. Therapeutic drug monitoring of anti-HIV drugs. International Congress Series 2001;1220:145-60. [DOI: 10.1016/s0531-5131(01)00294-1] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
25 Ungwitayatorn J, Samee W, Pimthon J. 3D-QSAR studies on chromone derivatives as HIV-1 protease inhibitors. Journal of Molecular Structure 2004;689:99-106. [DOI: 10.1016/j.molstruc.2003.10.036] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
26 de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. Drug Interactions Between Antiretroviral Drugs and Comedicated Agents: . Clinical Pharmacokinetics 2003;42:223-82. [DOI: 10.2165/00003088-200342030-00002] [Cited by in Crossref: 102] [Cited by in F6Publishing: 86] [Article Influence: 5.4] [Reference Citation Analysis]
27 Wahl LM, Nowak MA. Adherence and drug resistance: predictions for therapy outcome. Proc Biol Sci 2000;267:835-43. [PMID: 10819155 DOI: 10.1098/rspb.2000.1079] [Cited by in Crossref: 106] [Cited by in F6Publishing: 83] [Article Influence: 4.8] [Reference Citation Analysis]
28 Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. Interaction of Anti-HIV Protease Inhibitors With the Multidrug Transporter P-Glycoprotein (P-gp) in Human Cultured Cells: . Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;19:203-9. [DOI: 10.1097/00042560-199811010-00001] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 4.1] [Reference Citation Analysis]
29 Galatsis P. Chapter 31. To Market, To Market - 1996. Elsevier; 1997. pp. 305-26. [DOI: 10.1016/s0065-7743(08)61489-x] [Cited by in Crossref: 10] [Article Influence: 0.4] [Reference Citation Analysis]
30 Friedler A, Blumenzweig I, Baraz L, Steinitz M, Kotler M, Gilon C. Peptides derived from HIV-1 vif: a non-substrate based novel type of HIV-1 protease inhibitors 1 1Edited by J. Karn. Journal of Molecular Biology 1999;287:93-101. [DOI: 10.1006/jmbi.1998.2585] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
31 Hsu A, Granneman GR, Cao G, Carothers L, el-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, Leonard JM. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998;63:453-64. [PMID: 9585800 DOI: 10.1016/S0009-9236(98)90041-8] [Cited by in Crossref: 113] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
32 Davis DA, Read-Connole E, Pearson K, Fales HM, Newcomb FM, Moskovitz J, Yarchoan R. Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages. Antimicrob Agents Chemother 2002;46:402-8. [PMID: 11796349 DOI: 10.1128/AAC.46.2.402-408.2002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
33 Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev. 1999;39:211-238. [PMID: 10837775 DOI: 10.1016/s0169-409x(99)00027-7] [Cited by in Crossref: 96] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
34 Samuel R, Suh B. Antiretroviral therapy 2000. Arch Pharm Res 2000;23:425-37. [DOI: 10.1007/bf02976566] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
35 Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, Dennis S, Berg J, Erdman K, Leonard JM, Sun E. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998;42:2784-91. [PMID: 9797204 DOI: 10.1128/AAC.42.11.2784] [Cited by in Crossref: 115] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
36 Kumari G, Singh RK. Highly Active Antiretroviral Therapy for treatment of HIV/AIDS patients: Current status and future prospects and the Indian scenario. HIV & AIDS Review 2012;11:5-14. [DOI: 10.1016/j.hivar.2012.02.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
37 Antonioiribarren J, Labarga P, Rubio R, Berenguer J, Miró J, Antela A, González J, Moreno S, Arrizabalaga J, Chamorro L, Clotet B, Gatell JM, López-aldeguer J, Martínez E, Polo R, Tuset M, Viciana P, Miguel Santamaría J, María Kindelán J, Ribera E, Segura F. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004). Enfermedades Infecciosas y Microbiología Clínica 2004;22:564-642. [DOI: 10.1016/s0213-005x(04)73163-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Rice AP, Sutton RE. Targeting protein–protein interactions for HIV therapeutics. Future HIV Therapy 2007;1:369-85. [DOI: 10.2217/17469600.1.4.369] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
39 Frick LW, Adkison KK, Wells-knecht KJ, Woollard P, Higton DM. Cassette dosing: rapid in vivo assessment of pharmacokinetics. Pharmaceutical Science & Technology Today 1998;1:12-8. [DOI: 10.1016/s1461-5347(98)00010-8] [Cited by in Crossref: 56] [Article Influence: 2.3] [Reference Citation Analysis]
40 Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF, Gibbons SE, Breckenridge AM, Back DJ. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997;11:F29-33. [PMID: 9084785 DOI: 10.1097/00002030-199704000-00001] [Cited by in Crossref: 173] [Cited by in F6Publishing: 152] [Article Influence: 6.9] [Reference Citation Analysis]
41 Prebianca G, Marques MS, Bianchin MD, Contri RV, Külkamp-Guerreiro IC. Improved sensory properties of a nanostructured ritonavir suspension with a pediatric administration perspective. Pharm Dev Technol 2020;25:1188-91. [PMID: 32746682 DOI: 10.1080/10837450.2020.1805762] [Reference Citation Analysis]
42 Wintergerst U, Hoffmann F, Sölder B, Notheis G, Petropoulou T, Eberle J, Gürtler L, Belohradsky BH. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus: . The Pediatric Infectious Disease Journal 1998;17:495-9. [DOI: 10.1097/00006454-199806000-00012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.2] [Reference Citation Analysis]
43 Blumenzweig I, Baraz L, Friedler A, Danielson U, Gilon C, Steinitz M, Kotler M. HIV-1 Vif-Derived Peptide Inhibits Drug-Resistant HIV Proteases. Biochemical and Biophysical Research Communications 2002;292:832-40. [DOI: 10.1006/bbrc.2002.6732] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
44 Gill J, Feinberg J. Saquinavir Soft Gelatin Capsule: A Comparative Safety Review. Drug Safety 2001;24:223-32. [DOI: 10.2165/00002018-200124030-00005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
45 Chrusciel RA, Romines KR. Recent developments in HIV protease inhibitor research. Expert Opinion on Therapeutic Patents 2005;7:111-21. [DOI: 10.1517/13543776.7.2.111] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
46 Rubio R, Berenguer J, Miró JM, Antela A, Antonio Iribarren J, González J, Guerra L, Moreno S, Arrizabalaga J, Clotet B, Gatell JM, Laguna F, Martínez E, Parras F, Miguel Santamaría J, Tuset M, Viciana P. Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002. Enfermedades Infecciosas y Microbiología Clínica 2002;20:244-303. [DOI: 10.1016/s0213-005x(02)72804-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
47 Lüthi B, Huttner A, Speck RF, Mueller NJ. Methadone-induced Torsade de pointes after stopping lopinavir–ritonavir. Eur J Clin Microbiol Infect Dis 2007;26:367-9. [DOI: 10.1007/s10096-007-0293-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
48 Mehellou Y, De Clercq E. Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go? J Med Chem 2010;53:521-38. [DOI: 10.1021/jm900492g] [Cited by in Crossref: 280] [Cited by in F6Publishing: 243] [Article Influence: 21.5] [Reference Citation Analysis]
49 Xie X, Muruato AE, Zhang X, Lokugamage KG, Fontes-Garfias CR, Zou J, Liu J, Ren P, Balakrishnan M, Cihlar T, Tseng CK, Makino S, Menachery VD, Bilello JP, Shi PY. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. Nat Commun 2020;11:5214. [PMID: 33060595 DOI: 10.1038/s41467-020-19055-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 28.0] [Reference Citation Analysis]
50 Tarnawski AS, Ahluwalia A. Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs. World J Gastroenterol 2022;28:275-89. [PMID: 35110950 DOI: 10.3748/wjg.v28.i3.275] [Reference Citation Analysis]
51 Back DJ, Khoo SH, Gibbons SE, Barry MG, Merry C. Therapeutic Drug Monitoring of Antiretrovirals in Human Immunodeficiency Virus Infection: . Therapeutic Drug Monitoring 2000;22:122-6. [DOI: 10.1097/00007691-200002000-00026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
52 Izzedine H, Launay-Vacher V, Baumelou A, Deray G. An appraisal of antiretroviral drugs in hemodialysis. Kidney Int 2001;60:821-30. [PMID: 11532078 DOI: 10.1046/j.1523-1755.2001.060003821.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
53 Matsuwaki Y, Wada K, White TA, Benson LM, Charlesworth MC, Checkel JL, Inoue Y, Hotta K, Ponikau JU, Lawrence CB, Kita H. Recognition of fungal protease activities induces cellular activation and eosinophil-derived neurotoxin release in human eosinophils. J Immunol 2009;183:6708-16. [PMID: 19864598 DOI: 10.4049/jimmunol.0901220] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
54 Cato A 3rd, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998;63:414-21. [PMID: 9585795 DOI: 10.1016/S0009-9236(98)90036-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
55 Clay PG, Adams MM. Pseudo-Parkinson Disease Secondary to Ritonavir–Buspirone Interaction. Ann Pharmacother 2003;37:202-5. [DOI: 10.1177/106002800303700207] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]